Potent, selective and ATP-competitive mTOR inhibitor (IC50 vales are 2 and 10 nM at mTORC1 and mTORC2 respectively). Exhibits 1000-fold selecticity for mTOR over PI3K and ~100-fold selectivity when compared to 450 other protein kinases. Impairs cell growth and proliferation to a greater degree than rapamycin.
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.
References for Torin 1
Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.
Liu et al (2010)J Med CHem 53(19) : 7146-55
PubMedID: 20860370
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.
Thoreen et al (2009)J Biol Chem 284(12) : 8023-32
PubMedID: 19150980
Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1.
Francipane and Lagasse (2013)Oncotarget 4(11) : 1948-62
